RESUMO
The efficacy of phytogenic drug prolit septo in the complex treatment of patients with urolithiasis complicated by infectious-inflammatory process was evaluated. The effects of prolit septo were assessed by a comparative evaluation of the results of microbiological analysis of urine in 14 patients of main group and 12 patients of control group. Patients in both groups were matched by sex, age, and results of raiological, clinical, biochemical and microbiological methods of examination. For the treatment of 11 patients of the main group, prolit septo was applied in combination with standard anti-bacterial treatment, 3 patients received monotherapy with prolit septo within 3-6 weeks. The drug was administered at a dose of 1200 mg (2 capsules) 3 times a day. Twelve patients of the control group received only standard treatment. The duration of treatment in both groups was 1-2 weeks. It was found that combined therapy with prolit septo is more effective than standard antibacterial treatment. Against the background of combined therapy the disappearance of bacteriuria was noted in 54.5% of patients of main group compared with 8.3% of patients of control group.
Assuntos
Bacteriúria/tratamento farmacológico , Enterococcus faecalis/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , Fitoterapia , Urolitíase/tratamento farmacológico , Adulto , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Bacteriúria/complicações , Bacteriúria/diagnóstico , Creatinina/sangue , Quimioterapia Combinada , Enterococcus faecalis/fisiologia , Feminino , Infecções por Bactérias Gram-Positivas/complicações , Infecções por Bactérias Gram-Positivas/diagnóstico , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/diagnóstico , Klebsiella pneumoniae/fisiologia , Masculino , Pessoa de Meia-Idade , Phyllanthus , Extratos Vegetais/uso terapêutico , Urolitíase/complicações , Urolitíase/diagnóstico , Adulto JovemRESUMO
A comparison was made of chemoradiation lesions of lower urinary tract mucosa in urinary bladder (UB) cancer at stage T1-3N0-1MO and approaches to their treatment. An optimal algorithm of examination and treatment of the above patients with consideration of the disease stage and somatic status is proposed.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Radioterapia/efeitos adversos , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/radioterapia , Algoritmos , Cistite/induzido quimicamente , Cistite/patologia , Fracionamento da Dose de Radiação , Feminino , Humanos , Masculino , Dor/etiologia , Estudos RetrospectivosRESUMO
The report reviews the experience gained with radio- and chemotherapy-related injuries suffered by bladder cancer patients. It corroborates the opinion of most European specialists that indications for radical cystectomy be extended with due considerations of up-to-date potential in anesthesiology, extensive care and pharmacology. Possible untoward side effects of radiation and intravesical chemotherapy as well as means of solution of the problem are discussed. It is urgent considering the constantly growing number of such patients, their age and associated somatic problems.
Assuntos
Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Neoplasias da Bexiga Urinária/patologia , Bexiga Urinária/efeitos dos fármacos , Bexiga Urinária/efeitos da radiação , Administração Intravesical , Adulto , Idoso , Quimioterapia Adjuvante/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mucosa/efeitos dos fármacos , Mucosa/efeitos da radiação , Estadiamento de Neoplasias , Radioterapia Adjuvante/efeitos adversos , Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/radioterapiaRESUMO
An evaluation of damage caused by radiation and chemical drugs to urinary bladder mucosa in stage T1-T2N0V0 cancer is presented and therapeutic modalities are discussed. The authors summarize their experience and offer recommendations for optimal treatment of the disease. Also, suggestions are made how to work out indications and contraindications in dealing with a specific urinary bladder cancer vis-avis stage and possible complications.
